Clinical trials: Multiple Sclerosis-Relapsing-Remitting
Relapsing-Remitting Multiple Sclerosis
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
To determine if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to determine if, over time, BG00012 treatment can decrease the number of certain types of…
- Trial name
- CONFIRM (NCT00451451)
- Testing
- BG00012, Glatiramer Acetate
- Where
- 195 sites in United States, Belarus and 26 more
- Volunteers
- 1,417 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
Adherence Trial With MS LifeLines ® Services
This is a Phase IV study to compare the current level of MS LifeLines ® (MSLL) services (face-to-face nursing visits and phone contacts) with customized MSLL services, to determine the optimal services to enhance medication…
- Trial name
- NCT01905527
- Testing
- Standard Services of Group A (Group A1), Customized Services of Group A (Group A2), Group B
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing-Remitting
A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
The primary objective of this study is to evaluate the radiological efficacy of SC natalizumab over time through Week 24 in natalizumab-naïve participants, as measured by brain magnetic resonance imaging (MRI).
- Trial name
- NCT05532163
- Testing
- Natalizumab
- Where
- 2 sites in Germany
- Volunteers
- 1 people
- Sponsor
- Biogen
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Optic Neuritis, Eye Diseases
- Trial name
- RETIMUS (NCT04289909)
- Testing
- Adaptive Optics Ophthalmoscopy (AOO)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Relapsing-Remitting Multiple Sclerosis (RRMS)
Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab
The primary objective of the study is to evaluate the effects of treatment with daclizumab on the proportion of participants relapse-free at 6 months in Relapsing-Remitting Multiple Sclerosis (RRMS) participants, who switched…
- Trial name
- SUSTAIN (NCT02881567)
- Testing
- Daclizumab
- Where
- 11 sites in United States, Canada and 3 more
- Volunteers
- 41 people
- Sponsor
- Biogen
Relapsing-Remitting Multiple Sclerosis
A fMRI(Functional Magnetic Resonance Imaging) Research Study to Learn More About Multiple Sclerosis and Individuals Potentially Experiencing Memory Difficulties
The purpose of this study is to determine if medication designed to improve memory will help patients with Multiple Sclerosis (MS) who are experiencing memory problems using fMRI to track brain activity.
- Trial name
- NCT00315367
- Testing
- Donepezil HCI (drug)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Neurognostics
Multiple Sclerosis
Multiple Sclerosis Self Monitoring Study
This study is a multicenter, prospective, randomized controlled trial (RCT) to compare the effectiveness of a smartphone-based self-monitoring and self-management tool on control self-efficacy with respect to standard clinical…
- Trial name
- MSSM (NCT06125301)
- Testing
- MS Sherpa
- Where
- Netherlands
- Volunteers
- 225 people
- Sponsor
- Amsterdam UMC, location VUmc
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
This study will evaluate the efficacy and safety of ocrelizumab in participants with RRMS who have had a suboptimal response to an adequate course of DMT.
- Trial name
- NCT02637856
- Testing
- Ocrelizumab
- Where
- 82 sites in United States, Canada
- Volunteers
- 608 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Relapsing-Remitting
Photobiomodulation Therapy in Persons With Multiple Sclerosis
This study will test whether photobiomodulation therapy improves muscle endurance and decreases inflammation in persons with relapsing-remitting multiple sclerosis. We will also investigate mechanisms for any improvements.
- Trial name
- NCT03691766
- Testing
- Photobiomodulation Therapy
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Marquette University
Multiple Sclerosis
Study on Cognitive Disorders of Multiple Sclerosis
The purpose of this study is to determine if memantine is effective in the treatment on cognitive disorders of Relapsing - Remitting multiple sclerosis. m
- Trial name
- NCT01074619
- Testing
- Memantine
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Caen
Relapse Remitting Multiple Sclerosis
Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis
The purpose of this research is to find out how the T regulatory (Treg) cells control autoimmune response in multiple sclerosis.
- Trial name
- NCT04857489
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Relapsing Remitting Multiple Sclerosis
Simvastatin in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Using Avonex Compared to Placebo
Patient with relapsing remitting multiple sclerosis taking avonex are included in this double blind randomized control trial. Simvastatin is compared to placebo.
- Trial name
- irmsrct (NCT00668343)
- Testing
- simvastatin
- Where
- Iran
- Volunteers
- 80 people
- Sponsor
- Tehran University of Medical Sciences
Relapsing Remitting Multiple Sclerosis
How Side Effects of Avonex Are Affected by Gradually Increasing to Full Dose vs Starting at Full Dose
This study is to find out if starting at low dose Avonex and slowly increasing to full dose will improve flu like symptoms as a side effect of Avonex treatment.
- Trial name
- TODAY (NCT00574041)
- Testing
- Interferon beta-1a
- Where
- Australia
- Volunteers
- 19 people
- Sponsor
- Biogen
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
General Note: throughout this record, "Rebif® New Formulation" is used for historical and consistency purposes. Objectives: Primary: To evaluate the efficacy of Rebif® New Formulation (Interferon-beta-1a [IFN-beta-1a], RNF)…
- Trial name
- IMPROVE (NCT00441103)
- Testing
- Rebif® New Formulation (IFN-beta-1a, RNF)
- Volunteers
- 180 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsing-Remitting Multiple Sclerosis
Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remitting Multiple Sclerosis in Egypt
The purpose of this observational study is to evaluate the Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients with Relapsing-Remitting Multiple Sclerosis in Egypt
- Trial name
- NCT05423769
- Testing
- Fingolimod
- Where
- 2 sites in Egypt
- Volunteers
- 30 people
- Sponsor
- Hikma Pharmaceuticals LLC
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive
Open-label Study of Liothyronine in MS
This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
- Trial name
- NCT02506751
- Testing
- liothyronine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Johns Hopkins University
Multiple Sclerosis, Relapsing-Remitting
Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis
The trial will study 2 doses of Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified (IGIV-C) for the number of relapses that occur in a 1 year treatment period.
- Trial name
- PRIVIG (NCT00220779)
- Testing
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified, Albumin (Human) 25%, United States Pharmacopeia (USP)
- Where
- 37 sites in United States, Austria and 10 more
- Volunteers
- 128 people
- Sponsor
- Grifols Therapeutics LLC
Relapsing Remitting Multiple Sclerosis
Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis
A Double Blind, Randomised, Placebo Controlled Study Investigating Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis in patients treated with Copaxone for at least 3 months
- Trial name
- NCT00429442
- Testing
- Simvastatin
- Where
- Denmark
- Sponsor
- Anna Tsakiri
Relapsing Remitting Multiple Sclerosis (RRMS)
Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod
This study evaluated disease control during different lengths of treatment transition from natalizumab to fingolimod.
- Trial name
- TOFIINGO (NCT01499667)
- Testing
- Fingolimod
- Where
- 44 sites in Australia, Austria and 9 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants…
- Trial name
- OBSERVE (NCT01462318)
- Testing
- Midazolam, Caffeine, S-warfarin
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 133 people
- Sponsor
- Biogen